ecancer

💫 Wrapping up the iBeCHANGE Annual Meeting in Palermo! Two days of collaboration and insights- from behavioural research and pilot study progress to AI-driven tools for cancer prevention. Thank you to all the partners for your contributions. 🌱 #CancerPrevention #EUProjects

Compartiendo con @EnriqueSoto8 de @CUCancerCenter en una JORNADA inspiradora con profesionales y pacientes con la #Oncología con "Common Sense" de fondo Gracias a @CMMetastasico, @ecancer,@FundacionUc3 y a los avales de @_SEOM @KingsCollegeLon @Fundacion_PORIB, @csoncol

⚙️💬Spotlight on innovation Silvia Orte and Noelia Martinez Molina from @Eurecat_news presenting on the Virtual User AI-based data-driven model, exploring how AI supports behaviour-focused prevention. #iBeCHANGE #AI #DigitalHealth #EUProjects

📍 Day 2 of the iBeCHANGE Annual Meeting is underway in Palermo From digital tools to AI-driven approaches, partners continue advancing cancer prevention research. 💻 Join the session: lnkd.in/gYYUCZ6F #iBeCHANGE #CancerPrevention #EUProjects #PublicHealth

📸 Live from the event: Ruth Cooper (@ecancer) interviews David Suñol from @Eurecat_news, Technical Lead of the iBeCHANGE project and leader of WP4. #iBeCHANGE #EUProjects #CancerPrevention

Leading experts share the most impactful #mRCC data from #GU26. @DrChoueiri @ViktorGruenwald @bergsa83 Dr Suarez & @g_develasco discuss key updates in advanced RCC, including IO-based combinations and new data from recent studies. Watch the discussion👉bit.ly/4lA74Sw

Broadcasting live Saturday 14th March at 14:15 GMT from #EAU26 . Tune in for free at ecancer.org/EAU #bladdercancer #NMIBC #urology

🌟Improving Treatment Strategies for Urothelial Carcinoma🌟 By @SoaresAndrey @OncoAlert @ecancer 👏🎓Outstanding talk by Dr. Andrey Soares at the XII Latin American Congress of Palliative Care (#ALCP2026). A pleasure to share the panel discussing the evolving landscape of perioperative management and advanced urothelial carcinoma. Key takeaways: 🔬 utDNA as a biomarker: clearance after neoadjuvant therapy correlates with higher pathologic complete response (pCR) and improved outcomes. 🧬 Immunotherapy-driven responses: deeper responses and potential impact on micrometastatic disease. 📊 Neoadjuvant immunotherapy: prospective trials showing pCR rates ~30–50% in urothelial carcinoma. ⚖️ Adjuvant therapy debate: limited benefit in patients achieving pCR, highlighting the need for better patient selection. 🚀 Future direction: integration of ADC + immunotherapy and molecular biomarkers to personalize perioperative treatment. @ASCO @myESMO @MedicalwatchHQ #UrothelialCancer #BladderCancer #Immunotherapy #PrecisionOncology #Biomarkers #ADC #GUOncology #CancerResearch #ALCP2026 #PalliativeCare

Oncology with Common Sense in Metastatic Breast Cancer - ecancer @ecancer oncodaily.com/voices/ecancer… #OncoDaily #Oncology #Cancer #Health #Medicine #BreastCancer #MetastaticBreastCancer #MedX #MedTwitter

Join us for an interactive seminar on 'Challenges in high-risk NMIBC: addressing current unmet needs to optimise patient care' live from #EAU26. Register for free here👇 ecancer.org/EAU #bladdercancer #urology #Oncology @jonathananing @amassonlecomte

ecancer.org/en/journal/art… @ecancer @AORTIC_AFRICA

Patient and public involvement in cancer care and research: the Indian perspective ecancer.org/en/journal/art… @CancerGridIndia @ecancer

Desde la #AECMM organizamos esta jornada junto a @ecancer el próximo 19 de marzo en Madrid. Si eres profesional de la salud y quieres profundizar en este enfoque, te esperamos. Más información👇 cancermamametastasico.es/jornada-sobre-… #CáncerMamaMetastásico

Excited to collaborate in this hybrid event (in-person/online) together with oncology professionals and patients, focused on the Common Sense Oncology movement @csoncol applied to Metastatic Breast cancer. 📅 March 19 Universidad Carlos.#Madrid @FundacionUc3 Below + information:

📅 International HPV Awareness Day HPV vaccination is a powerful tool to prevent cervical & HPV-related cancers. Simple SMS reminders can improve HPV vaccine uptake among adolescent girls in Kenya🇰🇪 Read more: ecancer.org/en/journal/art… #HPVAwarenessDay #EducationSavesLives

🔥 miR-371 in Stage I TGCT | CLIMATE Study #ASCOGU26 #GU26 Dr Samuel Funt @MSKCancerCenter @OncoAlert Precision surveillance is coming to testicular cancer. 🧬 miR-371 as MRD marker post-orchiectomy 📊 196 baseline samples • 40 recurrences • Detectable miR-371 strongly associated with relapse • 24-mo RFS: 98% (undetectable) vs 75% (detectable) • HR ~3.7 for recurrence 🧠 Outperformed: • Tumor size • LVI • Traditional clinicopathologic risk groups ⚖️ Practical advantages vs ctDNA: • Faster turnaround (~days) • Lower cost • No tissue requirement • Strong discrimination in seminoma & NSGCT 🚨 Key question: Is miR-371 ready to guide adjuvant decisions or risk-adapted surveillance? Trials like CLARITY are paving the way. Testicular cancer may be the next solid tumor where MRD truly reshapes management. @ecancer @MedicalwatchHQ #TesticularCancer #TGCT #MRD #miR371 #PrecisionOncology #Oncology

🔷 KEYNOTE-B15 / EV-304 (LBA630) Presented by Matthew D. Galsky, MD #ASCOGU26 #GU26 #BladderCancer @OncoAlert Perioperative EV + pembrolizumab vs neoadjuvant cisplatin + gemcitabine in cisplatin-eligible MIBC: 🔹 EFS: HR 0.53 (95% CI 0.41–0.70; P<0.001)   24-mo EFS 79.4% vs 66.2%   Median EFS NR vs 48.5 mo 🔹 OS: HR 0.65 (95% CI 0.48–0.89; P=0.009) 🔹 pCR: 55.8% vs 32.5%   Absolute difference +23.4% 🔹 Grade ≥3 TEAEs: 75.7% vs 67.2%   No unexpected safety signals 🧠 Scientific signals • Depth of pathologic response translates into EFS gain • First robust OS signal challenging perioperative cisplatin • ADC + IO strategy moving earlier in disease biology 📌 Comparative context After KEYNOTE-905 expanded EV+IO in cisplatin-ineligible disease, B15 now questions cisplatin as the reference backbone in eligible patients. 🟢 Clinical interpretation For fit MIBC patients, perioperative EV+pembro may become the new benchmark. The next strategic dilemma: sequencing after upfront EV exposure and real-world implementation. The perioperative landscape in bladder cancer is formally shifting. @MattGalsky @OncLive @UroToday @ecancer @urologysummit @MedicalwatchHQ #OncoAlertAF @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago #MIBC #EVPembro #Oncology

🔷 RC48G001 – Disitamab Vedotin in HER2-expressing UC (LBA631) Presented by Thomas Powles, MD @TomPowles1 @OncoAlert #ASCOGU26 #GU26 #BladderCancer Phase 2, global, single-arm study of disitamab vedotin (anti-HER2 ADC) in previously treated advanced urothelial carcinoma. Two cohorts: 🔹 Cohort A (HER2 3+ or 2+/ISH+) • ORR: 54.9% • CR: 16.9% • mPFS: 5.7 mo • mOS: 20.0 mo 🔹 Cohort B (HER2-low) • ORR: 52.6% • CR: 18.4% • mPFS: 5.7 mo • mOS: 17.0 mo Grade ≥3 TRAEs: 41% Discontinuation due to AEs: 16.6% Peripheral neuropathy 6% 🧠 Scientific signals • Activity observed across HER2-high and HER2-low • Consistent response rates beyond classic HER2 amplification paradigm • Manageable toxicity profile for an ADC backbone 📌 Biologic insight HER2 in urothelial carcinoma may function more as a spectrum than a binary biomarker — echoing the HER2-low revolution seen in breast oncology. 🟢 Clinical interpretation In the post-platinum/post-IO setting, DV shows meaningful activity and expands the ADC landscape beyond Nectin-4 targeting. The key questions ahead: biomarker refinement, sequencing vs EV, and positioning in HER2-low disease. HER2 may become the next competitive ADC battleground in bladder cancer. @ecancer @MedicalwatchHQ #HER2 #ADC #UrothelialCancer #GU26

🔷 EV/P Improves EFS & OS vs Cis/Gem — What Does It Mean? Discussion by Tyler F. Stewart, MD @MattGalsky @TomPowles1 @OncoAlert #ASCOGU26 #GU26 #BladderCancer KEYNOTE-B15 confirms: 🔹 EFS HR 0.53 → 2-yr EFS 79% vs 66% 🔹 OS HR 0.65 → 2-yr OS 87% vs 81% Across MIBC trials: • NIAGARA → HR 0.68 • KN-905 → HR 0.75 • B15 → HR 0.53 The signal is consistent: perioperative intensification improves outcomes. 🧠 But the real discussion starts here: • Is EV/P for everyone? • Global accessibility & cost • What happens if early progression after EV? • Sequencing in an ADC-saturated landscape 📊 ADC battlefield in bladder cancer expanding: Nectin-4 | HER2 | Trop-2 | SLITRK6 | Tissue Factor | B7-H3 HER2 story evolving: Biomarker remains imprecise — but generally, higher expression performs better. 🟢 Clinical interpretation EV/P is no longer experimental. It is becoming the perioperative reference point. But it is the beginning of a new sequencing era — not the end. The next frontier: molecular reassessment (ctDNA, utDNA, genomics) to personalize post-EV strategies. Bladder cancer is officially entering the ADC era. @ecancer @urologysummit @MedicalwatchHQ #OncoAlertAF @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago #MIBC #ADC #EVPembro #PrecisionOncology

PTEN-deficient mHSPC is no longer just a poor-prognosis label. #ASCO #GU26 #CAPItello-281 It may be a targetable biology. @OncoAlert @ASCO 🔬 Capivasertib + abiraterone vs abiraterone: 📈 rPFS: 33.2 vs 25.7 months HR 0.81 (95% CI 0.66–0.98) | p=0.034 Biomarker-selected benefit. 🧬 Why PTEN matters? Loss of PTEN → PI3K/AKT pathway activation → AR-independent survival signaling → Therapeutic vulnerability. This is biologic precision, not escalation for everyone. 📊 What about QoL? ✔ No clinically meaningful deterioration in FACT-P total score ✔ Physical wellbeing decline slightly earlier (expected with AKT AEs) ✔ Overall HRQoL preserved ✔ >80% continued treatment Targeted therapy without sacrificing function. ⚠ Common AEs (class-consistent): • Diarrhea • Rash • Hyperglycemia Mostly early. Mostly manageable. Dose modifications worked. 💡 My clinical take: We are entering an era where: mHSPC ≠ one disease PTEN-deficient ≠ standard ARPI alone The question is no longer: “Doublet or triplet?” It is: “Who needs pathway-specific targeting?” Capivasertib + abi may represent the first biomarker-driven strategy in mHSPC. That’s a paradigm shift. @DrGeorgeDuke @KarimFizazi @urotoday @ecancer @MedicalwatchHQ @ecancer_espanol